肿瘤相关皮肌炎患者的预后因素:一项纳入73例患者的回顾性多中心队列研究
该多中心回顾性队列纳入73例肿瘤相关皮肌炎患者,中位随访3.92年,采用含时间依赖协变量的Cox模型并以逆概率删失加权校正。皮肌炎完全临床缓解与肿瘤缓解(HR 2.46,95%CI 1.13-5.32)及较年轻年龄(HR 0.68,95%CI 0.49-0.95)相关;死亡风险与持续肿瘤活动(HR 12.93,95%CI 2.42-69.25)、男性(HR 2.82,95%CI 1.19-6.70)及较大年龄(HR 1.86,95%CI 1.26-2.79)相关,与持续皮肌炎活动无显著关联(HR 0.40,95%CI 0.13-1.26)。
要点
- 肿瘤缓解与皮肌炎完全临床缓解相关(HR 2.46,95%CI 1.13-5.32),较年轻年龄亦相关(HR 0.68,95%CI 0.49-0.95)。
- 持续肿瘤活动(HR 12.93,95%CI 2.42-69.25)、男性(HR 2.82,95%CI 1.19-6.70)及较大年龄(HR 1.86,95%CI 1.26-2.79)与死亡风险相关。
- 持续皮肌炎活动与死亡风险无显著关联(HR 0.40,95%CI 0.13-1.26),免疫抑制治疗与死亡率无显著关联。
核心结论
- 本研究提供强力证据表明皮肌炎与肿瘤的演变在总生存和皮肌炎完全临床缓解两方面均存在显著关联。
- 针对皮肌炎的免疫抑制治疗与死亡率无显著关联。
研究设计与样本
- 多中心、回顾性队列研究,纳入73例肿瘤相关皮肌炎患者。
- 采用含时间依赖协变量的Cox模型进行多变量生存分析,并以逆概率删失加权校正。
主要发现
- 中位随访3.92年;40例(54.8%)患者达到肿瘤缓解,其中28/40例(70.0%)达到皮肌炎完全临床缓解。
- 皮肌炎完全临床缓解与肿瘤缓解相关(HR 2.46,95%CI 1.13-5.32),与较年轻年龄相关(HR 0.68,95%CI 0.49-0.95)。
- 死亡风险与持续肿瘤活动相关(HR 12.93,95%CI 2.42-69.25),与男性相关(HR 2.82,95%CI 1.19-6.70),与较大年龄相关(HR 1.86,95%CI 1.26-2.79)。
- 死亡风险与持续皮肌炎活动无显著关联(HR 0.40,95%CI 0.13-1.26)。
- 口服糖皮质激素使用仅在单变量分析中为保护因素(HR 0.18,95%CI 0.08-0.42)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate factors associated with DM complete clinical response and overall survival with a focus on the use of immunosuppressive therapies in patients with cancer-associated DM. METHODS: We performed a multicentre, retrospective cohort study. Multivariable survival analyses used a Cox model with time-dependent covariates and adjustments with inverse probability censoring weighting. RESULTS: We included 73 patients with cancer-associated DM. Median follow-up was 3.92 years. Overall, 40 (54.8%) patients achieved cancer remission, with DM complete clinical response in 28/40 (70.0%). DM complete clinical response was associated with cancer remission (hazard ratio [HR] 2.46, 95% CI [1.13-5.32]) and younger age (HR 0.68, 95% CI [0.49-0.95]). Risk of mortality was associated with sustained cancer activity (HR 12.93, 95% CI [2.42-69.25]), male sex (HR 2.82, 95% CI [1.19-6.70]), and older age (HR 1.86, 95% CI [1.26-2.79]) but not sustained DM activity (HR 0.40, 95% CI [0.13-1.26]). Oral corticosteroid use was a protective factor only on univariate analysis (HR 0.18, 95% CI [0.08-0.42]). CONCLUSION: This study provides strong evidence of a significant association between the evolutions of DM and cancer, both in terms of overall survival and DM complete clinical response. Immunosuppressive treatments for DM were not significantly associated with mortality. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04637672.
引用
- Teboul A, Allenbach Y, Tubach F, et al. Prognostic factors for patients with cancer-associated dermatomyositis: a retrospective, multicentre cohort study of 73 patients. Rheumatology (Oxford). 2025. PMID: 39589730. doi:10.1093/rheumatology/keae629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。